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1. Introduction 
Inorganic lead is harmful to plants and animals. A 
major subcellular result of Pb 2 ÷ administration to rats 
is altered mitochondrial structure, including loss of 
cristae, and impaired phosphorylation performance 
when these organdies are subsequently isolated 
[1-3].  In vitro mitochondria bind and accumulate 
Pb 2÷ in the absence of Pi [4,5], and this alters 
respiration and substrate uptake [4-~8]. It has thus 
been suggested that mitochondria may be loci for 
Pb 2÷ toxicity in vivo [4,9]. However, despite the 
ubiquitous presence of phosphate in living organisms, 
many workers have stressed that in vitro the presence 
of this anion reduces or abolishes the effects of Pb 2÷ 
on mitochondria [4,6-9], because of the very low 
solubility product of lead phosphate (7.9 × 10 -43) 
[10], and the lack of interaction of the precipitate 
with mitochondria [9]. Thus, although the forma- 
tion in the mitochondrial matrix of granules, probably 
containing lead, has been reported after Pb 2÷ adminis- 
tration in vivo [11 ] and in vitro [12] and 21°Pb 
accumulates in mitochondria [ 13], no studies have 
been made of the effects of this cation on mito- 
chondrial phosphorylation in vitro, because this pro- 
cess requires added Pi" In this paper we report hat 
Pb 2÷ does inhibit phosphorylation, despite the 
presence of Pi, and show that certain chelating agents, 
notably ATP, exascerbate he deterioration i  phos- 
phorylation performance. 
2. Methods 
We prepared rat heart mitochondria as previously 
described [14], taking care to remove the 'fluffy 
layer' which often covers the mitochondrial pellet. 
The final mitochondrial suspensions were supplemented 
with 0.5 mg purified bovine serum albumin/mg pro- 
tein. We determined the effects of Pb 2+ on the phos- 
phorylation rates of mitochondria respiring on pyru- 
rate and malate, although rates, P/O ratios and 
respiratory control ratios usually varied in concert, as 
illustrated in fig.2. 
3. Results 
Even in the pressence of 4.7 mM Pi, without added 
adenine nucleotide, phosphorylation rates decline 
when Pb 2÷ is added in excess of about 100 nmol/mg 
protein (fig.l). The deterioration also increases with 
the time elapsing between Pb 2÷ administration a d 
the addition of ADP. In these respects, Pb 2÷ resembles 
Ca 2÷, but the two differ very significantly in the 
effect of ATP on the damage which they cause. Phos- 
phorylation of exogenous ADP before addition of 
Ca 2÷ lessens the decrease in phosphorylation rate 
caused by this cation in the presence of Pi [15], but 
the decrease caused by Pb 2÷ is much greater when it 
is added after an ADP cycle, and the extent of the 
deterioration is directly related to the amount of 
ADP phosphorylated before the administration f
Pb 2÷ (fig.2). We observed a similar effect on adding 
ATP as such, and found that when Pb 2÷ was added 
without he prior phosphorylation f ADP, of two 
subsequent phosphorylation cycles, the second was 
much worse than the first, due, we propose, to the 
ATP produced by the first cycle. ADP enters mito- 
chondria in exchange for internal ATP, which is also 
in dynamic equilibrium with external ATP [16]. Since 
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Fig. 1. Effect of Pb 2 * on the phosphorylation rate of rat heart 
mitochondria before and after the phosphorylation fadded 
ADP. 2.6 mg of mitochondrial protein was incubated in 150 
mM KC1, 10 mM Tris HEPES buffer at pH 7.0, and the Tris 
salts of pyruvate, malate and phosphate, ach at 4.7 mM, in a 
total volume of 3.25 ml at 27°C in a Clarke-type oxygen 
electrode. Various amounts of lead were added as 5 mM 
Pb(NO3)2 either with (e) or without (o) the prior phosphoryl- 
ation of 0.6 #mol of ADP. ADP was always added exactly 
2 min after the Pb 2+. Phosphorylation rates are expressed as 
percentages of the control rate obtained before the addition 
of Pb 2 *. When a prior phosphorylation cycle was included, 
this was used as the control; when it was not included the 
control was achieved by a separate run. The mean phosphoryl- 
ation rate in the absence of Pb 2÷ was 505 nmol ADP/mg 
protein/min. 
ATP also has a much higher affinity for Pb 2. than 
ADP [10], we believe that it is principally ATP which 
causes this increase in lead toxicity to mitochondria, 
through the solubilising effect of the formation of a 
Pb-ATP complex. Such complexes are known to 
increase the effective solubility of Pb2(PO4)3, or the 
more likely species PbHPO, [17], and we confirmed 
this by atomic adsorption spectroscopy. Fig.1 shows 
that the prior phosphorylation f 0.6 tamol ADP 
reduces the amount of Pb 2* which causes a decrease 
in phosphorylation rate in the presence of Pi by 
about an order of magnitude. We do not believe that 
ATP is acting as an additional energy source, thus 
increasing Pb 2÷ uptake, because of the similar effect 
achieved with other complexing agents, such as sucrose 
and dextran [18]. 
Citrate, another natural chelating agent which 
protects heart mitochondria against Ca 2÷ damage in 
the presence of Pi, by reducing both the rate and 
extent of its uptake [15], also increases the damage 
done by Pb 2÷ in the absence of added adenine 
nucleotide, although less so than does ATP (table 1). 
The presence of citrate does not result in additional 
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Fig.2. Effect of the length of a prior phosphorylation cycle 
on the Pba*-induced deterioration i phosphorylation 
performance of rat heart mitochondria 1.6 mg of mitochon- 
drial protein was incubated in the conditions described in the 
legend to fig.1. Various amounts of ADP were phosphorylated, 
then 100 nmol Pb(NO3) 2was added, and after exactly 2min, 
a further 0.5 umol ADP was added. The phosphorylation 
rates (e), P/O ratios (A) and respiratory control ratios (o) of 
the second ADP cycles are expressed aspercentages of the 
mean values achieved in five experiments inwhich 0.5 ~mol 
of ADP was added to mitochondria nthe absence of Pb 2÷. 
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Table 1 
Effect of  citrate on Pb 2÷ inhibition of mitochondrial 
phosphorylation rate in the presence of  Pi, with and 
without the phosphorylation of previously 
added ADP 
this agent is reported to cause [20], perhaps by 
pinocytosis [21 ], and suggests that the use of similar 
compounds in the treatment of Pb 2÷ poisoning will not 
damage mitochondria. 
Citrate Phosphorylation rate after Pb ~÷ as % of rate before 
conch. Pb 2 ÷ 
(mM) 
Rates -+ Pb 2 + deter- 
mined from different 
runs, i.e. effect of Pb 
in the absence of  add- 
ed adenine nucleotide 
Rates -+ Pb 2+ determined 
from the same run, i.e. 
effect of  Pb in the presence 
of added adenine nucleot- 
ide 
0.0 52 16 
2.3 30 25 
4.5 27 23 
9.0 - 17 
2.0 mg of mitochondrial protein was incubated in the condi- 
tions described in the legend to fig.1. ADP was added 0.6 
~mol at a time, before and/or after 250 nmol of  Pb2+; the 
ADP was added exactly 2 min after the Pb 2÷. When a prior 
phosphorylation cycle was included, this was used as the 
control; when it was not included, the control was achieved 
by a separate run. The mean phosphorylation rate in the 
absence of  Pb 2+ was 588 nmol ADP/mg protein/min. 
damage when Pb 2÷ is administered after ADP, and 
small amounts of citrate even have a small protective 
effect against he increased amage due to ATP 
(table 1). Heart mitochondria, in the presence of 
malate, take up citrate very slowly [19] which is 
why the increased Pb 2÷ damage caused in the presence 
of this anion is less than with ATP. The fact that 
whilst chelating some Pb 2÷ in the medium, citrate 
largely remains there explains why, in the presence of 
preformed ATP, it has a limited protective ffect. 
With rat liver mitochondria, into which citrate enters 
more freely [ 19], preliminary experiments indicate 
that it causes agreater increase in Pb 2÷ damage. 
Unlike ATP and citrate, EDTA, which forms a very 
stable chelate with Pb 2+ [10], prevents the effect of 
Pb 2÷ on phosphorylation performance. Since EDTA 
is unable to cross the inner mitochondrial membrane, 
this suggest that Pb 2÷ must not only be in a soluble 
form to inhibit phosphorylation, but must also be 
able to cross the inner membrane. The protection 
afforded by EDTA to mitochondria contrasts with the 
increased transfer across the plasma membrane which 
4. Discussion 
We have shown that despite the presence of Pi, low 
concentrations of Pb 2÷ do damage mitochondria, 
much more than might be expected from a simple 
consideration of the solubility of its phosphate, due 
to the solubilising action of natural chelating agents, 
especially ATP. Such an effect must be particularly 
great in cells and conditions in which the cytoplasmic 
ATP levels are high. One of the first symptoms of 
plumbism in man is anaemia, and Pb 2÷ inhibits several 
of the mitochondrial steps in haem biosynthesis. 
Enzymes affected by low levels of Pb 2÷ in vivo are 
located in the blood or the plasma membrane [22-24]. 
This, coupled with the ability of mitochondria to 
accumulate Pb 2÷ is consistent with our suggestion that 
after passage through the plasma membrane, which 
may occur with ease [13,25], intracellular Pb 2÷ will 
preferentially affect mitochondrial enzymes and func- 
tion, although non-mitochondrial enzymes may be 
inhibited in vitro [26]. This contrasts with the 
suggestion [21] that nuclear protein-Pb 2÷ inclusion 
bodies may be depots which effectively remove Pb 2÷ 
from the cytosol. 
In a KC1 medium with 2.5% dextran, and after the 
phosphorylation f 0.5 #mol ADP, we have shown a 
deterioration i phosphorylation rate in the presence 
of Pi after the administration of as little as 1 nmol 
Pb2÷/mg protein. Thus, assuming 35 mg mitochon- 
drial protein/g cardiac tissue [27], about 7 ppm of 
Pb 2÷ in heart tissue could affect phosphorylation, if 
it was all located in mitochondria, s evidence suggests 
it may be [13,25]. Although such concentrations 
were not found in heart muscle of normal or exposed 
individuals by Barry [28], they were found in other 
soft tissues, notably the aorta, and recalculation of 
data for occupationally exposed men recorded by 
Petkou et al. [29] gives values for Pb 2÷ in heart tissue 
of about 3.5 ppm. It is quite possible that conditions 
are such in vivo that lower levels of Pb 2÷ have effect, 
and that in our experiments some Pb 2÷ was precipi- 
tated even in the presence of ATP. We therefore sug- 
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2+ . . gest that the etiology of Pb toxicity, including 
possible neurological and behavioural disorders at 
what are regarded as normal evels, may have their 
origins in effects on mitochondria. 
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